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Background: Clinical guidelines recommend immediate initiation of
combined antiretroviral therapy for all HIV-positive individuals. How-
ever, those guidelines are based on trials of relatively young participants.
Methods: We included HIV-positive antiretroviral therapy–naive,
AIDS-free individuals aged 50–70 years after 2004 in the HIV-CAUSAL
Collaboration. We used the parametric g-formula to estimate the 5-year
risk of all-cause and non-AIDS mortality under (1) immediate initiation at
baseline and initiation at CD4 count, (2),500 cells/mm3, and (3),350
cells/mm3. Results were presented separately for the general HIV
population and for a US Veterans cohort with high mortality.
Results: The study included 9596 individuals (28% US Veterans)
with median (interquantile range) age of 55 (52–60) years and CD4
count of 336 (182–513) at baseline. The 5-year risk of all-cause
mortality was 0.40% (95% conﬁdence interval (CI): 0.10 to 0.71) lower
for the general HIV population and 1.61% (95% CI: 0.79 to 2.67) lower
for US Veterans when comparing immediate initiation vs initiation at
CD4 ,350 cells/mm3. The 5-year risk of non-AIDS mortality was
0.17% (95% CI: 20.07 to 0.43) lower for the general HIV population
and 1% (95% CI: 0.31 to 2.00) lower for US Veterans when comparing
immediate initiation vs initiation at CD4 ,350 cells/mm3.
Conclusions: Immediate initiation seems to reduce all-cause and
non-AIDS mortality in patients aged 50–70 years.
Key Words: aging, when to start, antiretroviral treatment, CD4 cell
count, causal inference, parametric g-formula, comparative effectiveness
(J Acquir Immune Deﬁc Syndr 2017;76:311–318)
INTRODUCTION
Two randomized clinical trials have shown that com-
bined antiretroviral therapy (ART) initiation at high CD4
counts reduces the risk of serious AIDS and non-AIDS events
and death in HIV-positive individuals.1,2 As a result, clinical
guidelines have been updated to recommend ART initiation
in all HIV-positive individuals regardless of their CD4 cell
count.3–5 However, these trials comprised relatively young
participants (median age 36 years) and the number of deaths
was too small to examine effects on mortality. Thus, estimates
of the impact of the new recommendations on mortality
among older HIV-positive individuals, whose prognosis may
be different, are currently lacking.
The number of patients diagnosed with HIV at older age
has increased over time.6 Currently, between 12% and 18% of
newly diagnosed HIV-positive individuals are older than 50
years in high-income countries.7,8 Compared with younger
HIV-positive patients, those who enter HIV care at older age are
often diagnosed with late or advanced HIV disease,6 have
a diminished immunological response to treatment,9–11 and are
therefore at higher risk of progressing to AIDS or death. The
clinical management of these patients is further complicated by
a higher prevalence of comorbidities, including hyperlipidemia,
cardiovascular disease, cancer, and diabetes.12 The beneﬁts of
immediate ART initiation might be partially or totally offset by
polypharmacy, ie, taking a large number of different medi-
cines,13 that can make adherence to ART more difﬁcult and can
increase the risk of drug toxicities and drug interactions.14
It is therefore important to quantify the impact of
immediate ART initiation in patients who enter into HIV care
at older age. Here we estimate the 5-year risk of all-cause
mortality and non-AIDS mortality among ART-naive, AIDS-free
individuals aged between 50 and 70 years using data from the
HIV-CAUSAL Collaboration of HIV cohorts from Europe and
the Americas. More speciﬁcally, we estimated and compared the
mortality risks if all participants had started ART (1) immedi-
ately, (2) when their CD4 count dropped below 500 cells/mm,3
and (3) when their CD4 count dropped below 350 cells/mm.3
We present the results separately for HIV-positive patients from
the general population and for US Veterans with high mortality.
METHODS
Selection of Patients
We included individuals aged between 50 and 70 years,
who had at least 1 CD4 cell count and 1 HIV-RNA measured
within 3 months of each other, whereas ART-naive and AIDS-
free after December 31, 2004. Baseline was deﬁned as the earliest
of the date when all the inclusion criteria were met. Individuals
older than 70 years at baseline were rare in our cohorts and were
not included because their clinical management might be
different due to a higher burden of comorbidities. We considered
2 populations with different background mortality: HIV-positive
patients from the general population and US Veterans known to
have higher mortality.15 Individuals from the general HIV
population were enrolled in the following cohorts: AMACS
(Greece), ANRS CO3 Aquitaine, French Hospital Database,
PRIMO, SEROCO (France), ATHENA (the Netherlands),
CoRIS, GEMES, PISCIS (Spain), IPEC (Brazil), Southern
Alberta Clinic Cohort (Canada), Swiss HIV Cohort study
(Switzerland), UK CHIC, and the UK Register of Seroconverters
(United Kingdom). The population of US Veterans included
individuals from the Veterans Aging Cohort Study (US).
ART Initiation Strategies
ART was deﬁned as a combination of antiretroviral drugs
including at least 2 nucleoside reverse transcriptase inhibitors
plus either 1 or more protease inhibitors, 1 nonnucleoside
reverse transcriptase inhibitor, 1 entry/fusion inhibitor, or 1
integrase inhibitor.
For each population, we estimated the 5-year risk of all-
cause mortality and non-AIDS mortality if all participants had
started ART within 3 months of baseline (immediate ART
initiation). We compared these estimates with those estimated
under ART initiation within 3 months of AIDS diagnosis or
CD4 count (1) ,500 and (2) ,350 cells/mm3, the ART
initiation strategies recommended in different settings before
the changes in guidelines. We did not account for episodes of
ART discontinuation and we assumed that once ART was
started, patterns of treatment discontinuation were the same as
in the observed data for each of the 2 populations.
Follow-up
Follow-up started at baseline and ended at the earliest of
death, 12 months after the most recent laboratory measurement,
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cohort-speciﬁc administrative censoring, date of pregnancy when
known, 5 years after baseline, or the date a patient initiated ART
with a combination other than our deﬁnition of ART.
Outcomes
The outcomes, which were analyzed separately, were all-
cause mortality and non-AIDS mortality up to 5 years after
baseline. For each ART initiation strategy and outcome, we
estimated the 5-year risk and risk difference. Non-AIDS
mortality was deﬁned as any known cause of death other than
AIDS-deﬁning conditions.16 Cause of death was based on the
International Classiﬁcation of Diseases 10th Revision (ICD-10)
and formatted according to CODE (http://www.hicdep.org/).
Two cohorts, UK CHIC and IPEC, did not provide data on
cause of death and were excluded from the non-AIDS mortality
analyses. For all cohorts, death ascertainment and cause of
death were based on hospital records and cross-matching with
national and local registries.15
Statistical Methods
Our estimates had to be adjusted for the time-dependent
confounders CD4 cell count, HIV-RNA level and AIDS, as
well as for confounders measured at baseline. Because standard
statistical methods cannot appropriately adjust for time-
dependent confounders affected by previous treatment,17,18
we applied the parametric g-formula to obtain adjusted
estimates for each treatment strategy under the assumptions
of no residual confounding, no measurement error, and no
model misspeciﬁcation.19
The parametric g-formula is a generalization of standard-
ization for time-varying treatments and confounders.17,20 The
parametric g-formula is used to estimate the risk of mortality that
would have been observed if all patients in the study had
perfectly complied with a particular treatment initiation strategy
and none had been lost to follow-up. The estimation procedure
for the HIV-CAUSAL Collaboration has been described
elsewhere.21 Brieﬂy, the procedure has 2 steps. First, parametric
regression models are used to estimate the joint distribution of
the outcome, treatment and time-varying covariates conditional
on previous treatment, and covariate history. Second, a Monte
Carlo simulation using the above estimates is run to simulate the
distribution of the postbaseline outcomes and time-varying
covariates separately under each ART initiation strategy.
For the ﬁrst step, we ﬁt separate logistic regression models
for time-varying indicators for the outcome event, AIDS, ART
initiation, measurement of CD4 cell count, measurement of
HIV-RNA, and linear regression models for CD4 cell count and
HIV-RNA on the natural logarithm scale. All regression models
included as covariates the most recent value of these time-
varying variables, time since last CD4 count and HIV-RNA
measurements, and the following baseline variables: CD4 cell
count (,100, 100–199, 200–349, 350–499, $500 cells/mm3),
HIV-RNA level (,10000, 10,000–100000, .100000 copies/
mL), age (,60, $60 years), sex, mode of acquisition (hetero-
sexual, homo/bisexual, injecting drug users, or other/unknown),
calendar year (2005–2009, 2010–2015), geographical origin
(Western countries, sub-Saharan Africa, other, unknown), and
cohort. All models also included an interaction term for number
of months since ART initiation.
In the analyses where the outcome was non-AIDS
mortality, AIDS mortality and mortality due to unknown cause
were treated as competing events. The g-formula estimates of risk
in the presence of competing risks should be interpreted as an
extension of the sub-distribution cumulative incidence function to
the setting of time-varying treatments and confounders.20
As in all regression-based methods, the parametric
g-formula relies on correct model speciﬁcation. To explore
the validity of our parametric assumptions, we compared the
observed means of the outcome and time-varying covariates
with those predicted by our models. We used a nonparametric
bootstrap procedure based on 500 samples to obtain percentile-
based 95% conﬁdence intervals (CIs). All analyses were
conducted with the publicly available SAS macro GFORMU-
LA (http://www.hsph.harvard.edu/causal/software/).
Sensitivity Analyses
Because our main analyses included all ART-naive
patients regardless of CD4 count at baseline in a sensitivity
analysis, we restricted to the subset of individuals in the
general HIV population with a CD4 count $500 cells/mm3 at
baseline. This sensitivity analysis was conducted only in the
general HIV population because there were not enough patients
and death cases to achieve good model ﬁt in the US Veterans.
Because a nonnegligible proportion of death events had
unknown cause of death, as a sensitivity analysis we estimated the
risks, risk difference, and risk ratio of non-AIDS mortality
assuming that all deaths due to unknown cause were non-AIDS
related. This extreme case scenario is unrealistic in practice, but
provides an illustration of how sensitive the analyses may be to
assumptions regarding the missing data on cause-speciﬁc
mortality.
RESULTS
Table 1 shows the baseline characteristics of the 9599
eligible individuals, of whom 2672 (28%) were US Veterans.
Patients were predominantly males and started follow-up before
2010. The median (interquartile range) age at baseline was 55
years (52–59) in the general HIV population and 56 years
(53–60) in US Veterans. The median (interquartile range) CD4
count at baseline was 354 cells/mm3 (203–530) in the general
HIV population and 284 cells/mm3 (128–471) in US Veterans
(Supplemental Digital Content Table 1, http://links.lww.com/
QAI/B65).
During a follow-up of 31,989 person years, 7247
individuals initiated ART, 295 individuals died in the general
HIV population, and 339 died in the US Veterans cohort. In the
general population, there were 124 (55%) non-AIDS deaths, 47
(21%) AIDS deaths, and 54 (24%) deaths with unknown cause.
The most common non-AIDS causes of death were non-AIDS
cancer (70 events) and cardiovascular disease (21 events). In
US Veterans, there were 136 (40%) non-AIDS deaths, 157
(47%) AIDS deaths, and 46 (14%) deaths with unknown cause.
Sixty-two non-AIDS deaths were attributed to non-AIDS
cancer and 45 to cardiovascular disease.
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Rates of all-cause mortality and non-AIDS mortality per
1000 person-years were 12.3 and 6.3, respectively, for the
general HIV population, and 42.4 and 9.7 for US Veterans
(Fig. 1). In both populations, the observed rates of all-cause
and non-AIDS mortality were higher for males and for
individuals with lower CD4 count and older age at baseline.
The estimated 5-year risk of all-cause mortality under
immediate ART initiation was 5.3% (95% CI: 4.5 to 6.2) in the
general HIV population and 14.4% (12.6–16.7) in the US
Veterans (Table 2). The 5-year risk of all-cause mortality was
0.40% (0.10–0.71) lower for the general HIV population and
1.61% (0.79–2.67) lower for US Veterans when comparing
immediate initiation vs initiation at CD4 below 350 cells/mm.3
The estimated risk of non-AIDS mortality was lower for
immediate ART initiation compared with initiation at CD4
,500 and,350 cells/mm3 in both populations (Table 2). More
speciﬁcally, the 5-year risk of non-AIDS mortality was 0.17%
(20.07 to 0.43) lower for the general HIV population and 1.0%
(0.31–2.0) lower for US Veterans when comparing immediate
initiation vs initiation at a CD4 of 350 cells/mm3. The effect
estimates were similar in a sensitivity analysis that classiﬁed all
unknown-cause deaths as non-AIDS related (Supplemental
Digital Content Table 2, http://links.lww.com/QAI/B65).
Among individuals in the general HIV population with baseline
CD4 count $500 cells/mm3, the estimated risks of all-cause
mortality were 2.8% (1.5–4.5) under immediate ART initiation,
3.7% (2.5–4.5) under initiation at CD4 ,500 cells/mm3,
and 4.4% (3.1–5.9) under initiation at CD4 ,350 cells/mm3
TABLE 1. Baseline Characteristics by Background Mortality Group, HIV-CAUSAL Collaboration 2005–2015
Baseline
Characteristics
General HIV Population US Veterans
Included
(%)
Initiators of ART
During Follow-up, %
Median (IQR)
Follow-up, mo
Included
(%)
Initiators of ART
During Follow-up, %
Median (IQR)
Follow-up, mo
CD4 count,
cells/mm3
,100 798 (12) 88 30 (13–54) 532 (20) 87 26 (12–53)
100–200 878 (13) 89 33 (15–57) 435 (16) 87 27 (14–54)
200–349 1725 (25) 85 35 (17–64) 626 (23) 83 29 (14–55)
350–499 1534 (22) 71 34 (15–62) 495 (19) 76 29 (13–60)
$500 1992 (29) 57 34 (15–62) 584 (22) 60 29 (14–57)
HIV-RNA,
copies/mL
,10,000 1612 (23) 58 35 (15–66) 686 (26) 63 38 (11–53)
10,000–100,000 2855 (41) 75 33 (15–62) 1266 (47) 81 30 (15–58)
.100,000 2460 (36) 85 33 (16–59) 720 (27) 87 27 (12–52)
Sex
Male 5493 (79) 76 34 (16–63) 2607 (98) 78 28 (13–56)
Female 1434 (21) 70 31 (14–58) 65 (2) 74 30 (15–50)
Mode of acquisition
Heterosexual 3149 (45) 73 32 (15–59)
Homo/bisexual 2960 (43) 77 39 (18–69)
Injection drug use 161 (2) 67 21 (11–45)
Other/unknown 657 (9) 70 26 (11–50) 2672 (100) 78 28 (13–56)
Geographical origin
Western Countries 4386 (63) 76 36 (16–66)
Sub-Saharan Africa 415 (6) 69 26 (11–51)
Rest of World 611 (9) 72 28 (14–51)
Unknown country 1515 (22) 73 31 (14–60) 2672 (100) (100R) 74 28 (13–56)
Calendar year
2005–2009 4212 (61) 77 52 (26–79) 1791 (67) 86 45 (23–67)
2010–2015 2715 (39) 71 19 (11–33) 88 (33) 80 15 (9–22)
Age at enrollment, yr
50–59 5384 (78) 74 34 (15–63) 1964 (73) 83 29 (13–58)
60–70 1543 (22) 78 34 (15–59) 708 (27) 87 25 (13–48)
HCV coinfection status
No 5201 (75) 80 35 (17–63) 1555 (58) 81 29 (14–56)
Yes 891 (13) 74 36 (17–72) 1069 (40) 75 28 (13–56)
Unknown 835 (12) 59 22 (11–46) 48 (2) 56 11 (8–18)
All patients 6927 74 34 (15–62) 2672 78 28 (13–56)
HCV, hepatitis C virus; IQR, interquartile range.
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(Table 3). The time-varying means predicted by our models
under observed ART initiation were similar to the observed
means in the original data (Supplemental Digital Content Figs.
1–3, http://links.lww.com/QAI/B65).
DISCUSSION
We estimated the effect of immediate ART initiation in
HIV-positive patients between the ages of 50 and 70 years who
were entering routine HIV clinical care. The 5-year risk of all-
cause mortality was 0.40% lower for the general HIV
population and 1.61% lower for US Veterans when comparing
immediate initiation vs initiation at a CD4 count of 350 cells/
mm3. This means that in a hypothetical cohort of 1000 patients,
immediate initiation would prevent between 4 and 16 deaths
over a 5-year period. The reduction in absolute risk was smaller
for non-AIDS mortality. Although small, the estimated beneﬁts
of immediate initiation on the all-cause mortality of these older
FIGURE 1. Rates (number of events
per 1000 person-years) of (A) all-
cause mortality and (B) non-AIDS
mortality by baseline characteristics
and by background mortality group,
HIV-CAUSAL Collaboration 2005–
2015.
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populations are larger than those estimated among all individ-
uals in the HIV-CAUSAL Collaboration (median age 37
years)22: the 7-year risk of all-cause mortality for immediate
initiation was only 0.25% (95% CI: 0.40 to 0.37) lower than
the risk under initiation at CD4 count ,350 cells/mm3. These
ﬁndings suggest that in older HIV-positive patients, the
beneﬁts of immediate ART initiation on mortality are not
offset by age-related comorbidities and potential effects
of polypharmacy.
Our ﬁndings expand results from randomized con-
trolled trials, such as Temprano and START in which older
HIV-positive patients were underrepresented and death events
were too few to examine the effect of immediate initiation on
mortality.1,2 Our results are also compatible with those of
a subgroup analysis in patients with age $50 in START,
which showed an increase of 2.24 events of serious diseases
per 100 years for deferred vs immediate ART initiation.23
Our analysis estimates the risk that would have been
observed if all patients in the study, regardless of their CD4
cell count at baseline, had followed each ART initiation
strategy. The small magnitude of the beneﬁt of immediate
initiation is not surprising as more than half of the included
patients had a CD4 cell count ,350 cells/mm3 at baseline. In
analyses including only individuals in the general HIV
population with CD4 cell count $500 cells/mm3 at baseline,
the risk differences were larger: 1.62% for immediate
initiation vs initiation with CD4 ,350 cells/mm3. This
ﬁnding suggests that the beneﬁt of immediate ART initiation
in older HIV patients is greater when HIV infection is
diagnosed early, which stresses the importance of scaling
up testing programs. The high proportion of patients with low
CD4 cell count at baseline observed in our data is consistent
with reports of late HIV diagnosis among older HIV patients
in observational studies and surveillance data.7,24–27 Lower
CD4 cell count at entry into care in older patients can be due
to long periods being unaware of their positive HIV status
ands faster progression of the HIV disease in patients who
become infected at older age.28–30
The rates of all-cause and non-AIDS mortality were
higher for the US Veterans than for the general HIV population
which included individuals in Europe, Canada, and Brazil. The
difference in mortality is likely due to a combination of
heterogeneity in the data collection protocols and individual
characteristics. A contributing factor is the ascertainment of
death cases, which has been shown to be more complete in the
cohort of US Veterans.15 In addition to this, in our study, the
US Veterans had larger proportions of individuals older than
60 years at study entry and of hepatitis C virus coinfected
persons. Also, the US Veterans present substantial morbidity
and poor health compared with the general population.31
However, despite the difference in mortality, our effect
estimates were similar in both populations.
Our conclusions indicating the beneﬁts of immediate
initiation are compatible with the results from a study using
routinely collected data in the United States32 and extend this
study by looking at more recent calendar period, an older age
group and non-AIDS mortality. Of note, the observed and
estimated 5-year risks under all ART initiation strategies in the
TABLE 2. Estimated 5-Year Risk of All-Cause Mortality Under 3 ART Initiation Strategies, HIV-CAUSAL Collaboration 2005–2015
All-Cause Mortality Non-AIDS Mortality
Population
ART Initiation
Strategy
5-year Risk,
% (95% CI)
Risk Difference
(95% CI)
Risk Ratio
(95% CI)
5-year Risk,
% (95% CI)
Risk Difference
(95% CI)
Risk Ratio
(95% CI)
General HIV
population
(N = 6927)
Immediate
universal
5.3 (4.5 to 6.2) 0 (Ref.) 1 (Ref.) 2.7 (2.1 to 3.4) 0 (Ref.) 1 (Ref.)
,500 cells/mm3 5.5 (4.8 to 6.3) 0.14
(0.04 to 0.28)
1.03
(1.01 to 1.06)
2.8 (2.2 to 3.5) 0.07
(20.03 to 0.16)
1.03
(0.99 to 1.06)
,350 cells/mm3 5.7 (5.1 to 6.6) 0.40
(0.10 to 0.71)
1.07
(1.02 to 1.15)
2.9 (2.3 to 3.7) 0.17
(20.07 to 0.43)
1.06
(0.97 to 1.16)
US Veterans
(N = 2669)
Immediate
universal
14.4 (12.6 to 16.7) 0 (Ref.) 1 (Ref.) 6.6 (5.2 to 8.9) 0 (Ref.) 1 (Ref.)
,500 cells/mm3 15.1 (13.3 to 17.4) 0.69
(0.32 to 1.13)
1.05
(1.02 to 1.08)
7.0 (5.6 to 9.2) 0.40
(0.13 to 0.84)
1.06
(1.02 to 1.13)
,350 cells/mm3 16.0 (14.5 to 18.4) 1.61
(0.79 to 2.67)
1.11
(1.05 to 1.18)
7.6 (6.4 to 9.9) 1.00
(0.31 to 2.00)
1.15
(1.04 to 1.30)
TABLE 3. Estimated 5-Year Risks of All-Cause Mortality Under 3 ART Initiation Strategies for Individuals With CD4 Cell Count
$500 Cells/mm3 at Baseline in the General HIV Population, HIV-CAUSAL Collaboration 2005–2015
Population
ART Initiation
Strategy
All-Cause Mortality
5-year Risk,
% (95% CI)
Risk Difference
(95% CI) Risk Ratio (95% CI)
General HIV
population
(N = 2072)
Immediate universal 2.8 (1.6 to 4.4) 0 (Ref.) 1 (Ref.)
,500 cells/mm3 3.7 (2.5 to 5.0) 0.86 (0.10 to 1.45) 1.30 (1.03 to 1.72)
,350 cells/mm3 4.4 (3.3 to 5.9) 1.62 (0.17 to 2.82) 1.56 (1.05 to 2.41)
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general HIV population were lower in our study. The better
prognosis demonstrated by our study may be due to the more
recent follow-up period (2005–2015 in our study and
1998–2010 in the American study) and a smaller proportion
of injecting drug users (2% in our study and 22% in the
American study).
Our study has several limitations. First, as in all
nonrandomized studies, the validity of our estimates relies
on the assumption of no unmeasured confounding. We
adjusted for the most important factors used to decide when
to initiate ART such as CD4 count, HIV-RNA, and AIDS.
However, we did not collect information on age-related
comorbidities and concomitant treatments. Had these char-
acteristics inﬂuenced the decision to initiate ART in older
HIV-positive patients then our estimates could be biased.
Second, our methods require that all models are correctly
speciﬁed. This condition cannot be guaranteed, but it seems
plausible because our models resulted in simulated data sets
with average outcome and time-varying covariates similar to
those in the original data. Third, cause-speciﬁc mortality was
unknown for a substantial proportion of patients. Therefore, our
estimates might underestimate the risk of non-AIDS mortality.
As expected, the estimated absolute risks of non-AIDS
mortality were higher in the sensitivity analysis assuming that
all deaths for unknown cause were non-AIDS deaths, although
risk differences and risk ratios were similar. Moreover, it has
been shown that the ICD10 classiﬁcation for cause of death in
individuals known to be HIV-positive tends to misclassify liver
disease–related mortality into AIDS-related mortality.33 Finally,
the cohorts included in the HIV-CAUSAL Collaboration are
not based on random samples of the HIV population, tend to
include many HIV seroconverters and might therefore not be
fully representative of HIV patients in care in high-income
countries. However, this concern is not supported by a recent
study showing that individuals enrolled in European cohorts
tend to have broadly similar characteristics at HIV diagnosis
and the HIV-positive individuals in European Surveillance
registries.34
In conclusion, immediate initiation of ART seems to be
beneﬁcial in reducing all-cause mortality in AIDS-free
patients aged 50 years or older, despite their low baseline
CD4 count. More effort should be made into diagnosing HIV
earlier, particularly in older patients to ensure timely initiation
of treatment and follow-up for concomitant comorbidities,
thereby maximizing the beneﬁt of early treatment for HIV.
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